PF-Atlas › Clinical Trials › NCT03262142

Targeted AntiBiotics for Chronic Pulmonary Diseases

Piperacillin/tazobactam · Phase 4

Registry ID
NCT03262142
Phase
Phase 4
Status
Terminated
Drug / intervention
Piperacillin/tazobactam
Sponsor
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Start
2018-01-10
Enrollment
51
Locations
1

About this trial

This is a prospective, randomized multi-center trial investigating the impact of lower airway infection with P. aeruginosa in COPD patients. The aim of the study is to evaluate if targeted antibiotic therapy against P. aeruginosa can improve the prognosis in patients with COPD. non-CF bronchiectasis (BE) and asthma.

View NCT03262142 on ClinicalTrials.gov →

Explore related

All Piperacillin/tazobactam trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03262142 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.